The Department of Field Internal Medicine focuses systematically on the specialized postgraduate level of medical studies in the branch of field internal medicine. This discipline deals with specific military problems, in particular with the problem of saving the lives of patients suffering from serious and life-threatening conditions of non-surgical character. Such injuries generally occur during mass disasters both in wartime and in peacetime.

In the Department of Field Internal Medicine the development of military internal medicine follows three basic directions or areas: therapy and prevention, pedagogical and educational methods, and scientific research:

• Work in therapy and prevention is essential for military internists, because it enables us to acquire and develop good professional aptitude and experience in care for the seriously ill.
• The pedagogical and educational aspect of our work follows from our therapeutic/preventive activities. The Department coordinates the Branch Council of Clinical Medical Fields and the Branch Council of Postgraduate Study for Doctorates in Accredited Disciplines of Field Internal Medicine (equivalent of Ph. D.).
• Scientific research is the Department´s third main area of activity. Essentially, it extrapolates the results of applied clinical research into specific military conditions and into medical care under field conditions.

In 2008 the research in the Department continued in the five basic fields:

• Haematology – growth of stem cells – preparation for bone marrow transplantation.
• Biochemical and electrophysiologic investigation and monitoring of acute coronary syndromes.
• Cardiotoxicity of antitumorous therapy.
• Diagnosis and therapy of hypercoagulative states – the monitoring of anticoagulant therapy.
• Global quality of life in patients who have undergone the hematopoietic stem cell transplantation.

Cooperation in the clinical research:

1. Haematopoietic stem cell transplantation. A role of cytokines in transplantation. Transplant-related complications and supportive care has continued.
2. A study in the application of enteral and parenteral nutrition in intensive metabolic care has continued.
3. The study of supraventricular tachycardias – electrophysiologic investigation and therapy including radiofrequency ablation has continued.
4. Participation (co-investigators) on international study IRIS – Immediate Risk-stratification Improves Survival, primary prevention of sudden cardiac death.
5. Cardiotoxicity of antitumorous therapy – the research project has continued.
6. Projects have been carried out in the field of determination and analysis of monoclonal immunoglobulins in the urine of patients with multiple myeloma.
7. New biochemical cardiac markers (cardiac troponin T, high sensitivity CRP, brain natriuretic peptide) – clinical and laboratory evaluation has continued.
8. Analysis of transplantation activities, indications and results in the Czech Republic – National Stem Cell Transplantation Registry.
9. Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FC-R) versus chemotherapy with Fludarabine and Cyclophosphamide (FC) alone in patients with previously untreated chronic lymphocytic leukemia. CLL – 8 / ML 17102 Protocol of the GCLLSG (German CLL Study Group) Dept. of Internal Medicine I, University Hospital Cologne, Germany.
10. GvHD prophylaxis with ATG-Fresenius S in allogeneic Stem Cell Transplantation from matched unrelated donors: A randomised phase III multicenter trial comparing a standard GvHD prophylaxis with cyclosporine A and methotrexate with additional pretransplant ATG-Fresenius S. Project-No. (Fresenius): AP–AS–21–DE, Project-No. (ZKS): S020801 Medizinische Klinik I, Universitätsklinikum Freiburg .
11. Research project: MZO 00179906 (Czech Ministry of Health), Bioindicators in Hematology and Internal Medicine.
12. A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin (Pre- and Post Chemotherapy and Pre-Chemotherapy only) for Reduction in Severity of Oral Mucositis in Subjects with Multiple Myeloma (MM) Receiving High Dose Melphalan followed by Autologous Peripheral Blood Stem Cell Transplantation (PBSCT): AMGEN, Protocol no. 20050219.
13. Military – medical aspects of war surgery and war internal medicine (MO0FVZ0000503).